Ayubu Mdetele B, Kidima Winifrida B
College of Natural and Applied Sciences, University of Dar es Salaam, P.O. Box 35064, Dar es Salaam, Tanzania.
Malar Res Treat. 2017;2017:9761289. doi: 10.1155/2017/9761289. Epub 2017 Mar 30.
Intermittent preventive treatment using SP (IPTp-SP) is still a superior interventional approach to control malaria during pregnancy. However its rate of use has gone down tremendously in malaria endemic areas. This study forms part of a larger study aimed at monitoring the compliance of IPTp-SP policy in malaria endemic areas of Tanzania. Two cross-sectional studies were conducted in Dar es Salaam and Njombe Regions of Tanzania. Overall, 540 pregnant women and 21 healthcare workers were interviewed using structured questionnaires. This study revealed that 63% of women were not willing to take SP during pregnancy while 91% would only take it if they tested positive for malaria during antennal visits. 63% of the interviewed women did not know the recommended dose of SP required during pregnancy, despite the fact that 82% of the women were aware of the adverse effect of malaria during pregnancy. It was found out that 54% of pregnant women (30-40 weeks) took single dose, 34% took two doses, and 16% did not take SP at the time of interview. It was also found that SP was not administered under direct observed therapy in 86% of women. There was no significant relationship between number of doses received by pregnant women and antenatal clinic (ANC) start date ( = 0.0033, 95% CI (-0.016 to 0.034)). However positive correlation between drug uptake and drug availability was revealed ( = 0.0001). Knowledge on adverse effects of placental malaria among pregnant women was significantly associated with drug uptake (OR 11.81, 95% CI (5.755-24.23), = 0.0001). We conclude that unavailability of drugs in ANC is the major reason hindering the implementation of IPTp-SP.
使用磺胺多辛-乙胺嘧啶(IPTp-SP)进行间歇性预防治疗仍然是孕期控制疟疾的一种优越的干预方法。然而,在疟疾流行地区,其使用率已大幅下降。本研究是一项更大规模研究的一部分,旨在监测坦桑尼亚疟疾流行地区IPTp-SP政策的依从性。在坦桑尼亚的达累斯萨拉姆和恩泽姆贝地区进行了两项横断面研究。总体而言,使用结构化问卷对540名孕妇和21名医护人员进行了访谈。本研究表明,63%的女性在孕期不愿意服用磺胺多辛-乙胺嘧啶,而91%的女性只有在产前检查疟疾检测呈阳性时才会服用。63%的受访女性不知道孕期所需的磺胺多辛-乙胺嘧啶推荐剂量,尽管82%的女性知道疟疾在孕期的不良影响。结果发现,54%的孕妇(30 - 40周)服用了单剂量,34%服用了两剂,16%在访谈时未服用磺胺多辛-乙胺嘧啶。还发现86%的女性未在直接观察治疗下服用磺胺多辛-乙胺嘧啶。孕妇接受的剂量数与产前诊所(ANC)开始日期之间无显著关系( = 0.0033,95%置信区间(-0.016至0.034))。然而,揭示了药物摄取与药物可获得性之间存在正相关( = 0.0001)。孕妇对胎盘疟疾不良影响的知晓与药物摄取显著相关(比值比11.81,95%置信区间(5.755 - 24.23), = 0.0001)。我们得出结论,产前诊所药物不可获得是阻碍IPTp-SP实施的主要原因。